Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”) today announced that CEO Lars
Kongsbak will be presenting at the J.P. Morgan 28th Healthcare Conference to be
held on 11-14 January 2010 in San Francisco.

The annual J.P. Morgan event is the most visited investor conference of its
kind.

This year, the company will present its new products for quantitative,
high-throughput real-time PCR analysis of miRNAs and its use in sensitive miRNA
biomarker profiling in challenging sample formats such as serum/plasma and FFPE
preserved tissue. By the launch of the qPCR products, Exiqon offers a complete
product line for miRNA analysis which includes sample preparation, a variety of
products for expression analysis and functional analysis. Furthermore, Exiqon
will present its novel and robust qPCR platform for miRNA-based diagnostics
including a pipeline update.

Exiqon's presentation is scheduled for 14 January at 12 noon (PST). Interested
parties are invited to see the presentation on the investor section of Exiqon's
website at www.exiqon.com.

Additional information: Lars Kongsbak, CEO, phone +45 4566 0888 (cell: +45 4090
2101)
Hans Henrik Chrois Christensen, CFO, phone +45 4566 0888 (cell: +45 4090 2131)

About Exiqon:
Exiqon's products are based on the proprietary LNA™ technology. This
technology offers unique advantages for detection of miRNA biomarkers for life
science researchers, drug developers and cancer treating physicians working
towards personalizing medicine. Exiqon operates in two business areas: Exiqon
Life Sciences has established a position for itself as one of the market's
leading providers of miRNA research products for miRNA analysis in cells.
Research products are used by academia, biotech and pharmaceutical companies
around the world to make groundbreaking discoveries about the correlation
between gene activity and the development of cancer and other diseases. Exiqon
Life Sciences is also collaborating with pharmaceutical companies in their
effort to develop new medicines based on miRNA as biological markers (Exiqon
Pharma Services). Exiqon Diagnostics is developing a series of new molecular
diagnostic products based on miRNA. Exiqon's goal is to gain a market-leading
position for miRNA-based diagnostics. Exiqon is listed on the NASDAQ OMX in
Copenhagen. For more information about us, please visit www.exiqon.com.

See the full press release in the attached PDF or at
www.exiqon.com/investor/portal.

press_release_uk_jpm_conference_091221_final.pdf